Myopathy Clinical Trials

307 recruitingLast updated: May 21, 2026

There are 307 actively recruiting myopathy clinical trials across 54 countries. Studies span Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1. Top locations include Boston, Massachusetts, United States, New York, New York, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Myopathy Trials at a Glance

307 actively recruiting trials for myopathy are listed on ClinicalTrialsFinder across 6 cities in 54 countries. The largest study group is Not Applicable with 74 trials, with the heaviest enrollment activity in Boston, New York, and Houston. Lead sponsors running myopathy studies include Bristol-Myers Squibb, China Immunotech (Beijing) Biotechnology Co., Ltd., and China National Center for Cardiovascular Diseases.

About Myopathy Clinical Trials

Looking for clinical trials for Myopathy? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myopathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myopathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 307 trials

Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

Non-obstructive Hypertrophic CardiomyopathyObstructive Cardiomyopathy, Hypertrophic
Lexicon Pharmaceuticals500 enrolled108 locationsNCT06481891
Recruiting
Phase 2

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Non-obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals, Inc.165 enrolled67 locationsNCT07023614
Recruiting
Phase 4

Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy (HCM)
Oregon Health and Science University40 enrolled2 locationsNCT07600177
Recruiting
Phase 4

DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis

Cardiometabolic Risk FactorsCirrhosisCirrhotic Cardiomyopathy+1 more
Post Graduate Institute of Medical Education and Research, Chandigarh400 enrolled1 locationNCT07322237
Recruiting
Phase 2Phase 3

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

DermatomyositisIdiopathic Inflammatory MyopathyAnti-synthetase Syndrome+5 more
Cabaletta Bio74 enrolled35 locationsNCT06154252
Recruiting
Not Applicable

Exercise Prescription in Children With Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy Without Obstruction
Alder Hey Children's NHS Foundation Trust10 enrolled1 locationNCT07595354
Recruiting
Phase 3

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals1,250 enrolled223 locationsNCT07052903
Recruiting

A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China

Hypertrophic Cardiomyopathy
Bristol-Myers Squibb500 enrolled15 locationsNCT07361289
Recruiting
Phase 3

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

CardiomyopathiesAmyloidosisHeart Diseases+3 more
Eidos Therapeutics, a BridgeBio company587 enrolled101 locationsNCT06563895
Recruiting

Development of CIRC Technologies

Heart FailureCardiovascular DiseasesAtrial Fibrillation+7 more
The Cleveland Clinic1,000 enrolled1 locationNCT05654272
Recruiting

AIC Genotyping Study

CardiomyopathyAtrial Fibrillation (AF)Genetic
Barts & The London NHS Trust299 enrolled1 locationNCT07574697
Recruiting

National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry

Sudden Cardiac DeathArrhythmogenic Right Ventricular DysplasiaCardiomyopathy, Dilated+11 more
Hospital do Coracao1,211 enrolled27 locationsNCT06546137
Recruiting
Not Applicable

NLRP3 Inflammasome and Physical Therapy in ICU-Acquired Weakness

Critical Illness Myopathy
University of Chile24 enrolled3 locationsNCT07017517
Recruiting

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

ObesityCardiomyopathyLi-Fraumeni Syndrome+3 more
National Heart, Lung, and Blood Institute (NHLBI)5,000 enrolled3 locationsNCT01143454
Recruiting
Phase 1

A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy

Dilated Cardiomyopathy (DCM)
Rocket Pharmaceuticals Inc.8 enrolled3 locationsNCT07137338
Recruiting
Not Applicable

FAPI PET/CT Imaging in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) (FAPI-ARVC))

Cardiac Magnetic Resonance ImagingArrhythmogenic Right Ventricular CardiomyopathyFAPI PET
Istanbul University - Cerrahpasa15 enrolled1 locationNCT07563660
Recruiting
Phase 4

A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis

Transthyretin Amyloid Cardiomyopathy
Bayer50 enrolled10 locationsNCT07298044
Recruiting
Phase 1

Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases

Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Neuromyelitis Optica Spectrum Disorder (NMOSD)+6 more
Polina Stepensky120 enrolled1 locationNCT07085676
Recruiting
Not Applicable

Is There a Genetic Predisposition for Acute Stress-induced (Takotsubo) Cardiomyopathy

Takotsubo Cardiomyopathy
University of Aberdeen700 enrolled2 locationsNCT04513054
Recruiting
Phase 1

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

Rheumatoid ArthritisSystemic Lupus ErythematosusSystemic Sclerosis+1 more
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company270 enrolled54 locationsNCT05869955